European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
Dec 12

European equities traded in the US as American depositary receipts were on the rise late Thursday morning, increasing 0.82% to 1,663.66 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and biopharmaceutical firm Cellectis (CLLS), which rose 4.6% and 3.9%, respectively. They were followed by telecommunications company Nokia (NOK) and pharmaceutical firm Novo Nordisk (NVO), which advanced 3.6% and 2.6% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and medical device maker EDAP TMS (EDAP), which fell 3.8% and 1.7% respectively. They were followed by oil and gas company Eni (E) and petroleum refiner Equinor (EQNR), which were off 0.2% each.

From the UK and Ireland, the gainers were led by cruise line operator Carnival (CUK) and biopharmaceutical company Akari Therapeutics (AKTX), which increased 4% and 3.4% respectively. They were followed by communications company WPP (WPP) and alcoholic beverage company Diageo (DEO), which were up 3% each.

The decliners from the UK and Ireland were led by biopharmaceutical firms Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 8.7% and 3%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and medical device manufacturer Smith & Nephew (SNN), which lost 1.9% and 1.7% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10